The authors evaluated the rapid antidepressant efficacy of ketamine in a large group of patients with treatment-resistant major depression. Ketamine demonstrated rapid antidepressant effects in an optimized study design, further supporting NMDA receptor modulation as a novel mechanism for accelerated improvement in severe and chronic forms of depression.
Ketamine is a “Dangerous Drug” (controlled substance) under the Dangerous Drugs Ordinance [New Version], 1973. Ketamine is stored and used in KetaMind Clinic only by licensed physicians, in accordance with Sec. 11(2) of the Dangerous Drugs Ordinance and Regulation 16 16 of the Dangerous Drugs Regulations, 1979, and subject to medical discretion. Nothing in this website should be construed as an inducement or recommendation of using ketamine or any other Dangerous Drug not in compliance with applicable laws or not in accordance with medical prescription.
Ketamine products used in KetaMind Clinic are medicinal products which are registered in Israeli but not approved for mental health indications. Accordingly, use of ketamine products is made under Regulation 29(a)(10) of the Pharmacists Regulations (Medicinal Products), 1986, and subject to special prescriptions which are submitted to the Ministry of Health’s review. Nothing in this website should be construed as an inducement or recommendation of using ketamine products not in accordance with their terms of registration or not in accordance with medical prescription.
